Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer (PARTACER-Suisse)

NCT07617610 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT07617610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07617610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer (PARTACER-Suisse)
Lead sponsor
Swiss Cancer Institute
Phase
Observational
Overall status
Recruiting
Start date
May 25, 2025
Completion date
September 30, 2030
Enrollment
30 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600e mutation, metastatic colorectal cancer